2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Philip W. Kantoff, MD, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer.
Philip W. Kantoff, MD, chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care® winner for Genitourinary Cancer, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer (mCRPC).
Many novel drugs have been introduced into the paradigm of mCRPC over the past decade. However, many of these agents have been moved into earlier lines of treatment for men with metastatic hormone-sensitive prostate cancer or nonmetastatic CRPC, says Kantoff.
For example, androgen-signaling agents or newer generation antiandrogens, such as enzalutamide (Xtandi), darolutamide (Nubeqa), apalutamide (Erleada), and abiraterone acetate (Zytiga) have been moved into earlier lines of therapy, Kantoff says. Additionally, sometimes docetaxel is brought into earlier lines of treatment.
As a result, the mCRPC setting is in need of additional treatment options, Kantoff explains.